Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from CanSino Biologics, Inc. Class H ( (HK:6185) ).
CanSino Biologics Inc. has announced the agenda for its 2024 Annual General Meeting, scheduled for June 4, 2025, in Tianjin, China. The meeting will cover several key resolutions, including the approval of the 2024 financial reports, profit distribution plans, and reappointment of auditors. Additionally, shareholders will consider granting mandates for share issuance and repurchase, which could impact the company’s capital structure and market operations.
More about CanSino Biologics, Inc. Class H
CanSino Biologics Inc. is a biotechnology company based in China, primarily focused on the development and production of vaccines. The company is known for its innovative approach in the biopharmaceutical industry, targeting a global market with its wide range of vaccine products.
Average Trading Volume: 1,693,720
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.76B
For an in-depth examination of 6185 stock, go to TipRanks’ Stock Analysis page.